Summary
The AI-generated content largely does not address the provided OPZELURA prescribing information. It instead makes multiple claims about an Apotex ruxolitinib ANDA and about Jakafi manufacturing, none of which are supported by the supplied OPZELURA label excerpts. It also provides no concrete, label-based dosing/safety/admin claims to evaluate beyond reiterating label-excerpt context.
Category Scores
Accurate Statements
OPZELURA is a cream and specifies “Cream: 15 mg of ruxolitinib per gram (1.5%).”
OPZELURA Section 3
OPZELURA is for topical use only and not for ophthalmic, oral, or intravaginal use.
OPZELURA Sections 2.1 and 2.2
OPZELURA use in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.
OPZELURA Section 1.3
OPZELURA boxed warning categories include serious infections, mortality, malignancy, MACE, and thrombosis with risk-management instructions in Sections 5.1–5.5.
OPZELURA Sections 5.1–5.5
Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 due to potential increased systemic exposure of ruxolitinib.
OPZELURA Section 7
Unsupported Statements
“Apotex launched its ANDA for ruxolitinib on May 24, 2024.”
Not supported by the provided OPZELURA prescribing information excerpts.
“This May 24, 2024 filing is considered the first one for a generic version of ruxolitinib.”
Not supported by the provided OPZELURA prescribing information excerpts.
“Ruxolitinib is used to treat myelofibrosis.”
Not supported by the provided OPZELURA prescribing information excerpts (OPZELURA indications described are atopic dermatitis and nonsegmental vitiligo).
“Ruxolitinib is used to treat polycythemia vera.”
Not supported by the provided OPZELURA prescribing information excerpts.
“Ruxolitinib is used for graft-versus-host disease.”
Not supported by the provided OPZELURA prescribing information excerpts.
“The branded version of ruxolitinib, known as Jakafi, is manufactured by Incyte Corporation.”
Not supported by the provided OPZELURA prescribing information excerpts.
“During a 180-day period of market exclusivity, the FDA cannot approve other ANDAs for the same drug.”
Not supported by the provided OPZELURA prescribing information excerpts.
“Filing an ANDA signifies a company's intention to market a generic equivalent of an already approved drug.”
Not supported by the provided OPZELURA prescribing information excerpts.
“The first company to submit a substantially complete ANDA may be eligible for a 180-day period of market exclusivity.”
Not supported by the provided OPZELURA prescribing information excerpts.
Contradictions
Important Omissions
No evaluation of OPZELURA’s specific labeled indications (atopic dermatitis and nonsegmental vitiligo), dosing regimen details (thin layer twice daily; BSA limits), or OPZELURA-specific contraindications/precautions beyond general references, despite the presence of relevant label text in the prompt.
Importance:
Moderate
No adverse reaction listing or monitoring details are provided from the label (e.g., infection monitoring/interrupting therapy; skin examinations for non-melanoma skin cancers), despite boxed-warning context being available.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most unsupported claims concern ANDA/process and other indications for ruxolitinib brands; they do not directly give OPZELURA dosing/safety instructions. However, the response fails to correctly ground several ruxolitinib indication statements in the provided OPZELURA label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple key statements are not supported by the provided OPZELURA prescribing information excerpts and introduce unrelated ANDA/manufacturing/other ruxolitinib indications.
Suggested Improvement
Limit evaluation and claims strictly to the provided OPZELURA label excerpts (Sections 1–7 and relevant boxed-warning content). Avoid generic ruxolitinib indications (myelofibrosis, polycythemia vera, GVHD) unless explicitly present in the supplied label text.